Drug intelligence / Profile preview

PC-0126

Development stage: Preclinical
Lead developer: Changtai Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

PC-0126 is a small molecule antineoplastic agent being developed by Changtai Pharmaceutical (also known as PharmaMax Corp) for the treatment of multiple tumors. Formulated as an oral tablet, the drug is part of a broader oncology pipeline that includes candidates for non-small cell lung cancer (PC-0119), acute myeloid leukemia (PC-0120), and colorectal cancer (PC-0121). While its specific molecular targets have not been publicly disclosed in the company's pipeline, its classification as a small molecule for multiple tumors suggests it may function as a multi-target kinase inhibitor or a similar targeted therapy. The drug is currently in the development stage, leveraging Changtai's expertise in innovative drug design and complex formulations.

Beyond the preview

Go deeper on PC-0126.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PC-0126.

Explore the full profile